← All trials
NCT05353192
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- Feb 28, 2025
- Completion date
- Feb 28, 2025
- First posted
- Apr 29, 2022
- Last posted
- Apr 29, 2022
- Enrollment
- 38
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GeneScience Pharmaceuticals Co., Ltd.Lead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Nanjing Medical UniversityCollaborator
- Nanjing Medical UniversityOverall official - principal investigator
- Shandong Provincial HospitalCollaborator
- Shandong Provincial HospitalOverall official - principal investigator
- Shengjing HospitalCollaborator
- Capital Medical UniversityCollaborator
- Capital Medical UniversityOverall official - principal investigator
- Chongqing Medical UniversityCollaborator
- Chongqing Medical UniversityOverall official - principal investigator
- Fudan UniversityCollaborator
- Fudan UniversityOverall official - principal investigator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityOverall official - principal investigator
- Jiangxi Children's HospitalCollaborator
- Jiangxi Children's HospitalOverall official - principal investigator
- China Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.